Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 16, 2024$3.74
P/E Ratio
N/A
Market Cap
$615.61M
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Overview
Trading Information
Company